Nicotine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Nicotine: From Nicotine Dependence to Exercise-Induced Malignant Hyperthermia
One-Sentence Summary
Nicotine is used in nicotine replacement therapy and is originally indicated for nicotine dependence (the knowledge graph also lists pellagra and beriberi). The TxGNN model predicts it may be effective for exercise-induced malignant hyperthermia, but no clinical trials and no publications support this prediction. It is a model-only prediction and does not appear to be biologically plausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Nicotine dependence (per the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Exercise-induced malignant hyperthermia |
| TxGNN Prediction Score | 83.91% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 10 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, nicotine is an agonist of nicotinic acetylcholine receptors, and its efficacy in nicotine dependence (as replacement therapy) is established. Mechanistically, it is not clear that it applies to exercise-induced malignant hyperthermia.
Malignant hyperthermia involves dysregulated calcium release through ryanodine receptors in skeletal muscle. Nicotine acts on nicotinic receptors at the neuromuscular junction and activates the sympathetic system, so it is more likely to be a risk than a benefit in this condition. The model score appears to reflect graph-based inference rather than a therapeutic link supported by data.
For context, the other predictions were reviewed. Only blepharospasm (rank 5) has direct human studies: two small pilot studies of nicotine nasal spray. They gave mixed results that lean negative, and botulinum toxin remains the standard of care. Predictions for migraine, oppositional defiant disorder, communication disorder and developmental mental health disorder rest mainly on epidemiologic literature that treats nicotine or smoking as a risk factor, not a treatment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11732P | NICOTINELL MINT LOZENGE 1 mg | Lozenge | Not stated |
| SIN16567P | NICORETTE QUICKMIST MOUTHSPRAY 1MG/SPRAY | Spray | Not stated |
| SIN14296P | Nicorette Invisi Transdermal Patch 25mg/16 hours | Extended-release patch | Not stated |
| SIN06529P | NICOTINELL TTS 30 TRANSDERMAL THERAPEUTIC SYSTEM 21 mg/24 hrs | Patch | Not stated |
| SIN12570P | NICOTINELL MINT 4MG CHEWING GUM | Chewing gum | Not stated |
Ten valid single-ingredient licences are registered in total; the five above are shown.
Safety Considerations
- Contraindications flagged in the knowledge graph (not taken from label text): cardiovascular disease (coronary artery disease, acute coronary syndrome, myocardial infarction, Prinzmetal angina), phaeochromocytoma and related adrenal/paraganglioma tumours, hyperthyroidism and Graves disease, diabetes mellitus and diabetic ketoacidosis, hyperglycaemia, peptic ulcer disease, liver disease, gallbladder disease, thrombocytopenia, blood coagulation disease, hypotensive disorders, gout, hemoglobinopathy, and substance abuse/dependence.
- Drug Interactions: 100 interactions were found. The notable one is bupropion (Moderate). Several H2 blockers are Minor: famotidine, ranitidine, cimetidine and nizatidine. Other listed interactions (for example pantoprazole, omeprazole, metformin, glimepiride, morphine and prednisone) have no severity grading.
- Theoretical concern for this prediction: nicotine's sympathetic activation and depolarising effect on neuromuscular receptors could worsen a hypermetabolic muscle crisis.
For package insert warnings, please refer to the product label.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has only a model score (83.9%), with no trials or publications. The known pharmacology suggests potential harm rather than benefit in malignant hyperthermia.
To proceed, the following is needed:
- Mechanism of action data and a documented biological rationale linking nicotine to ryanodine receptor or calcium dysregulation
- Preclinical evidence (for example muscle or animal models) showing benefit rather than a trigger effect
- Package insert warnings and contraindications from the Singapore regulator
- If a different indication is preferred, consider re-evaluating blepharospasm (the only prediction with direct human data) as a research question, noting that its evidence is old, small and leans negative
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.